Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMNA9KW)

Drug Name

CCT251545 Drug Info

Synonyms

1661839-45-7; 8-(3-chloro-5-(4-(1-methyl-1H-pyrazol-4-yl)phenyl)pyridin-4-yl)-2,8-diazaspiro[4.5]decan-1-one; CHEMBL3408213; 8-[3-chloro-5-[4-(1-methylpyrazol-4-yl)phenyl]pyridin-4-yl]-2,8-diazaspiro[4.5]decan-1-one; CCT-251545; 8-{3-Chloro-5-[4-(1-Methyl-1h-Pyrazol-4-Yl)phenyl]pyridin-4-Yl}-2,8-Diazaspiro[4.5]decan-1-One; GTPL8945; SCHEMBL17113515; CHEBI:143114; AMY16654; BCP17378; EX-A2539; BDBM50073190; NSC784591; s7981; ZINC212373586; CCT 251545; CS-5359; NSC-784591; AC-31717; HY-12681; DB-119021; CCT 251545;CCT-251545; CCT-251545;CCT 251545; Q27075796; 2,8-Diazaspiro[4.5]decan-1-one, 8-[3-chloro-5-[4-(1-methyl-1H-pyrazol-4-yl)phenyl]-4-pyridinyl]-; 4TV; 8-[3-Chloro-5-[4-(1-methyl-1H-pyrazole-4-yl)phenyl]-4-pyridyl]-2,8-diazaspiro[4.5]decane-1-one

Indication

Disease Entry	ICD 11	Status	REF
Colorectal cancer	2B91.Z	Preclinical	[1]

Cross-matching ID

PubChem CID: 77050682
ChEBI ID: CHEBI:143114
TTD Drug ID: DMNA9KW

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Patented Agent(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Cyclin-dependent kinase 8 (CDK8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SEL120	DMHCUZV	Acute myeloid leukaemia	2A60	Phase 1	[2]
Tricyclic benzimidazole derivative 1	DM5SD9E	N. A.	N. A.	Patented	[3]
Macrocycle derivative 14	DMXSRPH	N. A.	N. A.	Patented	[3]
Oxindole 94	DMPFD6Y	Pain	MG30-MG3Z	Investigative	[4]
Oxindole 16 (compound 3)	DMM5208	Discovery agent	N.A.	Investigative	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cyclin-dependent kinase 8 (CDK8)	TTBJR4L	CDK8_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Kinase inhibitors: the road ahead. Nat Rev Drug Discov. 2018 May;17(5):353-377.
2	Clinical pipeline report, company report or official report of Ryvu Therapeutics.
3	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
4	Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25.